| Document Date: 2013-03-14 08:26:22
Open Document File Size: 613,06 KBShare Result on Facebook
City New York / VB6-845 / Winnipeg / / Company IgG / Biotechnologyderived Pharmaceuticals / G.C. MacDonald (*) Viventia Biotechnologies Inc. / / Country Canada / / / Event Product Recall / FDA Phase / Product Issues / / IndustryTerm furin proteolytic site / cancer therapy / food consumption / treatment of cancer / treatment of cutaneous T cell lymphoma / light chain / / MedicalCondition leukemic cancers / EpCAM-positive tumor / T cell lymphoma / human tumor / solid tumors / bladder cancer / truncated Pseudomonas / EpCAM-negative melanoma / Melanoma / xenograft tumor / squamous cell carcinomas / solid cancers / lymphoid-derived tumor B / EpCAM-negative tumor / Median tumor / cancers / tumor / cancer / tumors / disease / transitional cell carcinomas / epithelial tumor / Mean tumor / SCID / carcinomas / maximum tumor / mm3 endpoint tumor / / MedicalTreatment immunization / immunotherapy / cancer therapy / / Organization National Institute of Health / ETA / FDA / / Person Jennifer Brown / Mark Kowalski / / Position representative / / Product Herceptin / Cisplatin / Rituxan / Cyclophosphamide / Bleomycin Sulfate / Avastin / Mitomycin / Bexxar / CL / Mylotarg / Vectibix / Etoposide / Paclitaxel / Campath / Zevalin / Erbitux / Fluorouracil / Ontak / I131 / BL22 / VB6-845 / VB4-845 / Erbitux™ (Cetuximab) / / ProvinceOrState Manitoba / / Technology immunotherapeutics / antibodies / SDH / Pharmacokinetics / drug delivery / Drug Discovery / treating cancer / /
SocialTag |
Chapter 19 The Preclinical and Clinical Evaluation of VB6845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors Joycelyn Entwistle, Mark Kowalski, Jennifer Brown,